Review Evaluates Sarcopenia, Frailty, and Obstructive Sleep Apnea in Upper Airway Disorders

A scoping review in Frontiers in Medicine indicates a conceptual overlap between obstructive sleep apnea, frailty, and sarcopenia, though direct evidence does not yet confirm a unified three-way clinical entity in head and neck cancer.

Researchers conducted a scoping review under PRISMA-ScR guidelines to analyze studies published between January 2015 and December 2025 regarding sarcopenia, frailty, and obstructive sleep apnea (OSA) in head and neck cancer (HNC) and upper airway disorders.

Out of 106 screened records, 12 studies were included in the final qualitative synthesis, showing that OSA correlates with frailty and sarcopenia-related phenotypes through intermittent hypoxia, systemic inflammation, and neuroendocrine dysregulation.

In HNC populations, pre-treatment sarcopenia and frailty were consistently associated with worse clinical outcomes, including postoperative complications, radiotherapy toxicity, and higher mortality.

The review found that direct evidence linking OSA with HNC within the analyzed studies was limited, meaning the proposed triad of OSA, sarcopenia, and frailty should be treated as a hypothesis-generating framework rather than an established clinical syndrome.

The findings suggest that existing imaging modalities (such as CT or MRI scans) can be leveraged to measure the skeletal muscle index (SMI) for rapid, non-invasive frailty and sarcopenia screening in oncology settings.

The correlation between nocturnal hypoxemia and muscle-related reserve supports a mechanistic link where treating sleep-disordered breathing could potentially preserve muscle health and mitigate frailty progression in older adults.

The review reinforces the growing clinical demand for therapeutic strategies addressing muscle preservation and sarcopenia to improve outcomes in geriatric oncology and chronic disease settings.

It highlights a potential patient-stratification paradigm, suggesting that trials evaluating muscle-preserving drugs could benefit from screening for sleep-disordered breathing or hypoxia-driven catabolic markers.

Prospective clinical studies that simultaneously integrate objective polysomnography (PSG) sleep testing, standardized frailty assessments, and CT/MRI-based muscle measurements in head and neck cancer cohorts to validate the proposed triad.